Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma To Pay Up $150m In US Opioid Settlement Framework

Company Faced Claims Of Failing To Report Suspicious Opioid Orders From 2006 To 2021

Executive Summary

Despite denying any wrongdoing, Hikma joins a group of companies that have agreed to pay big settlements for their alleged respective roles in the ongoing opioid epidemic in the US.

You may also be interested in...



‘Not Just Growth In AG Xyrem’ Hikma Underlines Following Strong 2023

Hikma welcomed a strong and profitable 2023, driven by the nourishing effects of its authorized generic Xyrem product, which will fall back this year as the rate of royalties owed to the brand’s innovator climbs. But the company is optimistic it can continue growth in 2024, including through its $1.2bn Injectables division, which rushed in to fill supply gaps last year.

Who’s Hired? Sandoz Freshens Up Directors Board After Pivotal Year

Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.

Mallinckrodt’s US Bankruptcy Approval Confirms $1bn Hit To Opioid Fund

Mallinckrodt is set to be in the hands of its lenders after a US bankruptcy court confirmed the company’s restructuring plan, which includes more than halving the $1.7bn previously promised to victims of the US opioid crisis.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel